Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENACWY=MEN7B-003 infant study
2023-506449-40-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of meningococcal ABCWY vaccine in meningococcal disease, Meningococcal B infection, Serogroup C meningococcal disease (MenC) and 1 more (2 arms), sponsored by GSK. Primary endpoints: Solicited administration site and systemic events, Unsolicited adverse events including MAEs, SAEs, AEs leading to withdrawal and AESIs (30 days) and 2 more. Started Jan 2024; status: completed.
02
Drugs
meningococcal ABCWY vaccine
03
Conditions
meningococcal diseaseMeningococcal B infectionSerogroup C meningococcal disease (MenC)invasive meningococcal disease (IMD)
Beyond the preview
Go deeper on 2023-506449-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506449-40-00.